These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32383803)

  • 1. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
    Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
    Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
    Yu Z; Zhang C; Wang H; Xing J; Gong H; Yu E; Zhang W; Zhang X; Cao G; Fu C
    Cancer Lett; 2014 Oct; 353(2):182-93. PubMed ID: 25088576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
    Park JH; Kim YH; Park EH; Lee SJ; Kim H; Kim A; Lee SB; Shim S; Jang H; Myung JK; Park S; Lee SJ; Kim MJ
    Cancer Sci; 2019 Sep; 110(9):2834-2845. PubMed ID: 31278880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
    Fernandes JM; Jandrey EHF; Koyama FC; Leite KRM; Camargo AA; Costa ÉT; Perez RO; Asprino PF
    Dis Colon Rectum; 2020 Jul; 63(7):918-926. PubMed ID: 32229782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
    Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H; Clamor C; Müller K
    J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X; Wei Y; Wei X
    Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM; Grothey A
    Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Napabucasin prevents brain injury in neuronal neonatal rat cells through suppression of apoptosis and inflammation.
    Wang J; Feng H; Li Z; Zhang X
    Microb Pathog; 2019 Mar; 128():337-341. PubMed ID: 30659911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
    Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
    J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
    Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z; Wang H; Ren H; Sun Y; Chen X
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.
    Chen J; Wang J; Lin L; He L; Wu Y; Zhang L; Yi Z; Chen Y; Pang X; Liu M
    Mol Cancer Ther; 2012 Feb; 11(2):277-87. PubMed ID: 22203730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3.
    Fan D; Liu P; Li Z; He X; Zhang L; Jiang W; Ang W; Yang T
    Bioorg Chem; 2024 Sep; 150():107565. PubMed ID: 38905884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
    Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.